Boehringer Ingelheim, Gubra Enter Third Obesity Deal
New pact builds on duo’s R&D activities begun in 2017
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
